ADHD Across the Reproductive Lifespan: A Clinical Frame

It is tempting to treat the hormonal exacerbation of ADHD as a perimenopause topic, and tempting again to reduce it to estrogen. It is more accurate, and more clinically useful, to hold two hormones across the whole arc — because they modulate two different systems, and the systems fail on different schedules.

Two hormones, two systems — why the full arc reframes a midlife presentation.

It is tempting to treat the hormonal exacerbation of ADHD as a perimenopause topic. It's important to see ADHD across the reproductive lifespan. This isn't just about estrogen. It is more accurate, and more clinically useful, to hold two hormones across the whole arc — because they modulate two different systems, and the systems fail on different schedules.

Two systems, not one

Estrogen and the dopaminergic system. Estrogen modulates dopaminergic tone, and ADHD is characterized in part by altered dopamine neurotransmission. The mechanistic claim has prospective support: within-person declines in estradiol predict higher next-day ADHD symptoms, with effects strongest in women high in trait impulsivity [1]. This is the accelerator — attention, motivation, drive.

Progesterone and the GABAergic system. Progesterone's neuroactive metabolite, allopregnanolone, is a potent positive allosteric modulator of the GABA-A receptor, the brain's primary inhibitory system, producing anxiolytic and sedative effects [5]. This is the brake — regulation, sleep, stress tolerance. Allopregnanolone dysregulation is documented across menarche, the menstrual cycle, the peripartum, and the menopausal transition, and is implicated in the mood vulnerability seen at each [5][6]. When we attend only to estrogen, we miss the system whose withdrawal often presents as the anxiety, irritability, and insomnia that get separately diagnosed and separately medicated.

A calibration worth carrying: "progesterone is calming" is an oversimplification. A subset of women — notably in PMDD — show altered allopregnanolone sensitivity at the GABA-A receptor, such that the same neurosteroid is anxiogenic rather than anxiolytic [6]. Individual response, and directionality, remain inconsistent in the literature. Hold the frame as a strong pattern, not a rule.

ADHD Across the Reproductive Lifespan: The arc, and what the evidence supports at each stage

Puberty. The onset of cyclical hormonal activity coincides with rising demand and, for many girls, the point at which a previously subclinical or inattentive presentation becomes impairing. Longitudinal work suggests symptom profiles shift across pubertal development rather than simply emerging [2].

Menstrual cycle. The best-characterized window. Symptom risk rises at points of rapid estrogen decline, clustering in the early luteal and perimenstrual phases and moderated by trait impulsivity [1][2]; the concurrent late-luteal fall in progesterone and allopregnanolone withdraws GABAergic support at the same moment [6]. (Developed in the companion cycle post.)

Menstrual-cycle chart (both versions): Across the month, estrogen and progesterone fall together before a period — a focus dip and a calm dip at once.

Pregnancy. A sustained high-hormone state with elevated allopregnanolone, associated in limited data with relative stability — though the small study base warrants caution against strong claims [2].

Postpartum. One of the steepest neurosteroid withdrawals in the lifespan: the precipitous fall in progesterone-derived allopregnanolone is central enough to peripartum mood pathology that a synthetic allopregnanolone analogue is now an approved treatment for postpartum depression [6]. Compounded by sleep disruption and caregiving load, this is an under-recognized window and, for some women, the first point of ADHD suspicion. The magnitude is worth carrying: in a 602-woman cross-sectional study, EPDS scores met the PPD threshold in 88.0% of women with ADHD versus 57.1% without (elevated antenatal, delivery, and postpartum complications alongside) [7].

Perimenopause and menopause. The most prolonged and erratic withdrawal — and clinically, the one where the two-system frame earns its keep. Progesterone typically declines first: as anovulatory cycles increase, the corpus luteum does not form, and progesterone (and its allopregnanolone) can fall well before estrogen does [6]. The GABAergic brake weakens first; the dopaminergic accelerator becomes erratic after — a two-hormone account the primary literature now echoes, noting that the perimenopausal decline in both estrogen and progesterone affects serotonergic and dopaminergic signaling [7]. Women with ADHD report more severe perimenopausal symptoms, with earlier onset than women without ADHD [3]. In Boyd et al.'s cohort, mean Greene Climacteric Scale total was 32.1 in the ADHD group versus 18.5 without (t=9.61, p<.001), with the psychological, anxiety, and depression subscales — not vasomotor — driving the difference [7].

Same hormones, no rhythm. As ovulation skips, progesterone can vanish before estrogen becomes erratic — the calm drops out first.

The ADHD in Women late-diagnosis pathway

This is the clinical payoff of holding the whole arc. The pattern is lifelong, but recognition frequently is not — because compensation absorbs the earlier, briefer withdrawals, and only the sustained perimenopausal one, hitting both systems at once, reliably overwhelms it. A midlife presentation of "new" executive dysfunction is therefore often not new at all, but a long-standing profile surfacing as scaffolding fails, frequently after prior misattribution to anxiety or depression [4]. The field has named the harms of late or incorrect diagnosis as a distinct priority [4].

Two assessment implications follow. First, a midlife presentation warrants a developmental history across the full reproductive arc — the pubertal account, the cyclical account, the postpartum account are each diagnostic data, and each should probe both the focus axis and the calm axis. Second, the failure of long-standing coping should be read as information about load and mechanism, not about effort or character.

Scope

Where hormonal assessment or medication questions arise — including the role of progesterone or estrogen therapy — those belong with the appropriate medical provider; STRAW+10 staging helps locate a client on the transition, but the prescribing decisions that follow are the medical lane's. Our work is the formulation, the meaning, and the developmental history the presentation sits on.

Continuing education

If you'd like to explore this further, Two CAMFT-approved CE courses on the intersection of trauma and hormonal transition:

• Menopause and Mental Health: A Comprehensive Framework — 6 CE

• Bridging the Gap: Perimenopause and Trauma — 2 CE, $33

Both are self-paced and CAMFT CE–approved (Provider #61115). To learn more or enroll, visit courses

---

References

1. Roberts B, Eisenlohr-Moul T, Martel MM. Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology. 2018;88:105–114. https://doi.org/10.1016/j.psyneuen.2017.11.015

2. Osianlis E, Thomas EHX, Jenkins LM, Gurvich C. ADHD and Sex Hormones in Females: A Systematic Review. Journal of Attention Disorders. 2025. https://journals.sagepub.com/doi/10.1177/10870547251332319

3. Perimenopausal symptoms in women with and without ADHD: A population-based cohort study. European Psychiatry. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538516/

4. Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease. Front Glob Womens Health. 2025. https://www.frontiersin.org/journals/global-womens-health/articles/10.3389/fgwh.2025.1613628/full

5. Allopregnanolone and Reproductive Psychiatry: An Overview. Int Rev Psychiatry (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC6594874/

6. Progesterone and Its Metabolites Play a Beneficial Role in Affect Regulation in the Female Brain. Pharmaceuticals (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143192/

7. Boyd C, Wrigley M, Kilbride K, Mulligan A, Bramham J. ADHD and the female reproductive stages: menstruation, perinatal and menopause. Archives of Women's Mental Health. 2026;29:89. https://doi.org/10.1007/s00737-026-01718-x

8. Supporting (menstrual-cycle mechanism, optional): Eng AG, Nirjar U, Elkins AR, et al. Attention-deficit/hyperactivity disorder and the menstrual cycle: Theory and evidence. Hormones and Behavior. 2024;158:105466. https://doi.org/10.1016/j.yhbeh.2023.105466About the Author

About the Author

Julie Cardoza, MS, LMFT is a licensed marriage and family therapist, EMDRIA Approved Consultant, and Certified EMDR therapist specializing in Somatic EMDR, based in California. She is a CAMFT-Approved Continuing Education Provider (#61115) and an IWHI Certified Perimenopause/Menopause Health Coach, and the founder of Heartscapes, LLC.

Julie specializes in the intersection of trauma, neurobiology, and hormonal transition, integrating Somatic EMDR, polyvagal-informed practice, and menopause-informed care. She provides consultation and continuing education for clinicians working where trauma and the menopause transition meet.

Disclaimer

This article is for educational and informational purposes only and does not constitute therapy, medical advice, or a therapeutic relationship. The content reflects the author's clinical perspective as a Licensed Marriage and Family Therapist in California and is not a substitute for individualized medical or mental health care.

Julie Cardoza provides therapy through her licensed private practice (juliecardoza.com) and coaching and education through Heartscapes, LLC (heartscapesllc.com). These services are distinct and offered under separate legal and ethical guidelines.

If you or a client is experiencing a mental health crisis, contact 988 (Suicide and Crisis Lifeline) or go to the nearest emergency room.

Land Acknowledgment

I acknowledge that I live and work on the traditional and ancestral lands of the Yokut and Mono peoples.